Post-Hoc: Lilly gets more secretive and hides Phase 1 pipelinenews2026-05-29T17:23:24+00:00May 29th, 2026|Endpoints News|
Lilly obesity meds Foundayo and Zepbound to gain CVS coveragenews2026-05-28T17:28:36+00:00May 28th, 2026|Endpoints News|
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapynews2026-05-28T13:38:47+00:00May 28th, 2026|Endpoints News|
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchasenews2026-05-28T11:20:41+00:00May 28th, 2026|Endpoints News|
WuXi Bio signs deal to manufacture Viridian’s thyroid eye disease drugnews2026-05-27T13:55:31+00:00May 27th, 2026|Endpoints News|
Lilly to acquire three vaccine biotechs for up to $3.8Bnews2026-05-26T11:20:08+00:00May 26th, 2026|Endpoints News|
Astellas’ five-year plan includes chasing record sales and cost cutsnews2026-05-26T11:10:04+00:00May 26th, 2026|Endpoints News|
FDA clears Gilead’s hepatitis D drug, four years after prior rejectionnews2026-05-22T18:35:28+00:00May 22nd, 2026|Endpoints News|
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel news2026-05-22T16:47:59+00:00May 22nd, 2026|Endpoints News|
Novartis says Avidity’s science could apply beyond muscular dystrophiesnews2026-05-22T13:00:54+00:00May 22nd, 2026|Endpoints News|
